Browsing by Author "Louw, V. J."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa
    (Health and Medical Publishing Group (HMPG), 2011-12) Louw, V. J.; Bassa, F.; Chan, S. W.; Dreosti, L.; Du Toit, M.; Ferreira, M.; Gartrell, K.; Gunther, K.; Jogessar, V.; Littleton, N.; Mahlangu, J.; McDonald, A.; Patel, M.; Pool, R.; Ruff, P.; Schmidt, A.; Sissolak, G.; Swart, A.; Verburgh, E.; Webb, M. J.
    Introduction. Myelodysplastic syndromes (MDS) encompass a heterogeneous group of clonal haematopoietic disorders characterised by chronic and progressive cytopenias resulting from ineffective haematopoiesis. Treatment is complicated by differences in disease mechanisms in different subgroups, variable clinical phenotypes and risk of progression to acute myeloid leukaemia. Rationale. Changes in disease classification, prognostic scoring systems, the availability of novel treatment options and the absence of South African guidelines for the diagnosis and management of these complex disorders underpinned the need for the development of these recommendations. Methods. These recommendations are based on the opinion of a number of experts in the field from the laboratory as well as clinical settings and came from both the private and institutional academic environments. The most recent literature as well as available guidelines from other countries were discussed and debated at a number of different meetings held over a 2-year period. Results. A comprehensive set of recommendations was developed focusing on risk stratification, supportive management and specific treatment. Novel agents and their indications are discussed and recommendations are made based on best available evidence and taking into account the availability of treatments in South Africa. Conclusion. Correct diagnosis, risk stratification and appropriate therapeutic choices are the cornerstones of success in the management of patients with MDS.
  • Thumbnail Image
    Item
    Recommendations for the management of sickle cell disease in South Africa
    (Health & Medical Publishing Group, 2014-11) Alli, N. A.; Patel, M.; Alli, H. D.; Bassa, F.; Coetzee, M. J.; Davidson, A.; Essop, M. R.; Lakha, A.; Louw, V. J.; Novitzky, N.; Philip, V.; Poole, J. E.; Wainwright, R.
    The spectrum of sickle cell disease (SCD) encompasses a heterogeneous group of disorders that include: (i) homozygous SCD (HbSS), also referred to as sickle cell anaemia; (ii) heterozygous SCD (HbAS), also referred to as sickle cell trait; and (iii) compound heterozygous states such as HbSC disease, HbSβ thalassaemia, etc. Homozygous or compound heterozygous SCD patients manifest with clinical disease of varying severity that is influenced by biological and environmental factors, whereas subjects with sickle cell trait are largely asymptomatic. SCD is characterised by vaso-occlusive episodes that result in tissue ischaemia and pain in the affected region. Repeated infarctive episodes cause organ damage and may eventually lead to organ failure. For effective management, regular follow-up with support from a multidisciplinary healthcare team is necessary. The chronic nature of the disease, the steady increase in patient numbers, and relapsing acute episodes have cost implications that are likely to impact on provincial and national health budgets. Limited resources mandate local management protocols for the purposes of consistency and standardisation, which could also facilitate sharing of resources between centres for maximal utility. These recommendations have been developed for the South African setting, and it is intended to update them regularly to meet new demands and challenges.